Report Highlights
The global market for oncology pharmaceuticals is estimated to increase from $196.4 billion in 2023 to reach $401.4 billion by 2029, at a compound annual growth rate (CAGR) of 12.7% from 2024 through 2029.
Report Includes
- 70 data tables and 50 additional tables
- Analysis of the global market for oncology pharmaceuticals (cancer drugs)
- Analyses of global market trends, with market revenue data from 2022 to 2023, estimates for 2024, forecast for 2025, and projected CAGRs through 2029
- An assessment of the different oncology pharmaceutical types (targeted therapy, immunotherapy, chemotherapy and hormone therapy) and their current and historical market revenues
- Estimate of the current market size and revenue prospects, along with a market share analysis by drug type, disease indication (application type), and region
- Facts and figures pertaining to the market dynamics, technological advances, regulations, and the macroeconomic factors that influence the industry
- A Porter’s Five Forces model, and global supply chain and PESTLE analyses
- An analysis of the key products on the market and promising new pipeline molecules or drugs under development
- A look at the recent patent grants
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, ESG score analysis, and the ESG practices of leading companies
- Analysis of the industry structure, including companies’ market shares, strategic alliances, M&A activity and a venture funding outlook
- Company profiles of major players within the industry, including Bristol-Myers Squibb Co., Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., and AstraZeneca.
Report Scope
This report seeks to deliver an in-depth analysis of the worldwide oncology pharmaceuticals (cancer medications) market. It includes a thorough overview of various types of oncology drugs, such as targeted therapy, immunotherapy, chemotherapy, and hormone therapy, and an examination of current and historical market revenues. The oncology pharmaceuticals market is further categorized by indication, including lung cancer, multiple myeloma, breast cancer, non-Hodgkin’s lymphoma, prostate cancer, colorectal cancer, and other types of cancer. Additionally, the report presents the market revenue for each geographic region, including North America, Europe, Asia-Pacific, and the Rest of the World (RoW).
In order to provide an in-depth understanding of the market, this report also includes profiles of market participants, the competitive landscape, key competitors, and respective market share/ranking. This report includes an oncology pharmaceuticals pipeline analysis, patent analysis, and a detailed discussion of key marketed products. This report outlines the driving and restraining factors of the oncology pharmaceuticals market.
By geography, the market in this report is segmented into four regions: North America, Europe, Asia-Pacific, and Rest of the World (RoW). For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029.
Report Synopsis
Report Metrics | Details | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Base year considered | 2023 | ||||||||||||
Forecast period considered | 2024-2029 | ||||||||||||
Base year market size | $196.4 billion | ||||||||||||
Market size forecast | $401.4 billion | ||||||||||||
Growth rate | CAGR of 12.7% for the forecast period of 2024-2029 | ||||||||||||
Units considered | $ Millions | ||||||||||||
Segments covered | Drug Type, Cancer Type, Region | ||||||||||||
Regions covered | North America, Europe, Asia-Pacific, Rest of the World | ||||||||||||
Key Market Drivers |
|
||||||||||||
Companies studied |
|
Frequently Asked Questions (FAQs)
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Report Highlights
The global market for oncology pharmaceuticals should grow from $177.4 billion in 2021 to $313.7 billion by 2026, at compound annual growth rate (CAGR) of 12.1% for the period of 2021-2026.
Report Includes
- 74 tables
- An overview of the global oncology pharmaceutical market
- Estimation of the market size and analyses of global market trends, with data from 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
- Highlights of the current and future market potential and quantification of oncology pharmaceutical market based on region, drug type, and application
- Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast
- Detailed description of risk factors, pathogenesis and stages of cancer including the TNM staging system and number staging systems, and coverage of cancer metastases, treatment approaches and non-pharmaceutical approaches to cancer
- Analysis of oncology pharmaceutical pipeline products with focus on promising pipeline molecules/ drugs in development, and coverage of technological advances, scientific discoveries, and new therapies
- Detailed analysis of the regulatory framework and policies, and snapshot of FDA approved drugs for indications related to oncology
- Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies and a relevant patent analysis
- Comprehensive company profiles of the leading players of the industry including AbbVie, Amgen, AstraZeneca, Bayer, Eli Lilly, F. Hofmann-La Roche, Johnson & Johnson, Novartis, and Pfizer
Related Reports
Artificial Intelligence (AI) in Cancer
The global market for artificial intelligence (AI) in cancer is estimated to increase from $2.2 billion in 2024 to reach $6.3 billion by 2029, at a compound annual growth rate (CAGR) of 23.1% from 2024 through 2029.
Multi-Cancer Diagnostic Tests: Global Market Outlook
This report provides an in-depth analysis of the global multi-cancer diagnostic (MCD) test market. It highlights the current and future market potential of the tests along with a detailed analysis of the drivers and challenges in the market. The report includes the company profiles of the key players with detailed information about their product portfolios and pipeline products.
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets
The global market for prostate cancer care is expected to grow from $37.9 billion in 2023 to $56.4 billion by the end of 2028, at a compound annual growth rate (CAGR) of 8.3% from 2023 through 2028.
Next-Generation Cancer Diagnostics: Technologies and Global Markets
The global next-generation cancer diagnostics market reached $8.7 billion in 2022 and should reach $15 billion by 2027, with a compound annual growth rate (CAGR) of 11.5% during the forecast period of 2022-2027.
Recent Reports
Rare Disease Diagnostics: Technologies and Global Markets
The global market for rare disease diagnostics is estimated to increase from $21.6 billion in 2024 to reach $34.7 billion by 2029, at a compound annual growth rate (CAGR) of 9.9% from 2024 through 2029.
Breakthrough Therapies: Market Dynamics and Investment Opportunities
The global market for breakthrough therapy drugs was valued at $133.3 billion in 2023. This market is expected to grow from $150.6 billion in 2024 to $287.5 billion by 2029, at a compound annual growth rate (CAGR) of 13.8% from 2024 to 2029.
Softgel Capsules: Global Markets
The global market for softgel capsules was valued at $7.4 billion in 2023. The market is expected to grow from $7.9 billion in 2024 to $11.5 billion by 2029, at a compound annual growth rate, or CAGR, of 7.7% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
Active Pharmaceutical Ingredients: Global Markets
The global market for active pharmaceutical ingredients (APIs) is estimated to increase from $247.8 billion in 2023 to reach $347.9 billion by 2029, at a compound annual growth rate (CAGR) of 5.9% from 2024 through 2029.
Top Trending Reports
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
Chronic Disease Management: Therapeutics, Device Technologies and Global Markets
The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.
Medical Devices Industry: Competitive Landscape
The global market for medical devices is estimated to increase from 810.4 billion in 2024 to reach $1.3 trillion by 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More